Citi downgrades BioMarin Pharmaceutical Inc (Nasdaq: BMRN) from Buy to Hold. Price target lowered from $42 to $37.

This article: 120 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE